Why the study?
Does oral tocainide reduce VPB activity compared to disopyramide in outpatients with stable ventricular premature beats?
Does oral tocainide reduce VPB activity compared to disopyramide in outpatients with stable ventricular premature beats?
Both oral tocainide and disopyramide effectively reduce ventricular premature beat frequency and grade during Holter monitoring, though their effects during exercise vary.
Answers are grounded in this paper and cite their sources.
Either drug may aid VPB suppression in stable outpatients; confirms Holter efficacy while leaving exercise response and safety open.
Oral tocainide and disopyramide were compared in a double-blind, crossover trial in 10 outpatients with stable ventricular premature beats (VPBs). Efficacy was assessed by suppression of VPB activity and reduction of VPB grade during an exercise test and an 18-h Holter recording. An estimate of variance of VPB activity was obtained from two separate placebo periods, and a 95% confidence limit for VPB suppression was calculated. During Holter recording, both drugs produced a significant reduction in VPB frequency and grade (p less than 0.05). During the exercise challenge, tocainide produced a reduction in VPB frequency and grade, but this did not reach statistical significance; VPB frequency was unaltered by disopyramide, but VPB grade was significantly reduced (p less than 0.01).
No takes yet. Share an insight, caveat, or question.
McLaran et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: